A Phase 2 interventional study of Surgical implantation of the CPCB-RPE1 implant in Dry Age-related Macular Degeneration and Geographic Atrophy, sponsored by Regenerative Patch Technologies, LLC. Recruiting at 5 sites in United States. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Regenerative Patch Technologies, LLC · Phase 2, Interventional, and Treatment
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 46 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 85th largest by planned enrollment of the 107 interventional ones, is one of 20 that started in 2025, is one of 43 in phase 2, reaches primary completion later than 20 of the 45 other live ones, and was the 101st registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
This study's planned enrollment of 24 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and 0 (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →131 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 20 started in 2025.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 78 that completed or were terminated, 40 (51%) have results posted.
109 of 131 have an industry lead sponsor. The 10 most frequent:
Regenerative Patch Technologies, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Regenerative Patch Technologies, LLC has 2 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
Up to 6 surgical implantation sites will deliver the CPCB-RPE1 in this Phase IIb clinical trial. Additional study sites may serve as referral or follow-up sites. Twenty-four (24) subjects will participate in the trial and will be randomized 3:1 to one of 2 groups:
Eligible participants include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active treatment group receiving the CPCB-RPE1 implant (up to 18 subjects).
Device: Surgical implantation of the CPCB-RPE1 implant
Control group receiving a simulated "sham" implantation procedure (up to 6 subjects)
Device: Surgical implantation of the CPCB-RPE1 implant
Surgical implantation of the CPCB-RPE1 implant
Change in retinal sensitivity
Change in retinal sensitivity by microperimetry
Time frame: 1 year post implantation
Change in best corrected visual acuity
Change in best corrected visual acuity
Time frame: 1 year post implantation
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.
Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regenerative Patch Technologies, LLC